TZIELD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TZIELD (TZIELD).
TZIELD (teplizumab) is a humanized anti-CD3 monoclonal antibody that binds to CD3 epsilon chain on T cells, thereby modulating T cell activation and expansion. It targets autoreactive T cells in type 1 diabetes, preserving pancreatic beta cell function.
| Metabolism | Teplizumab is a monoclonal antibody; metabolism is via catabolic pathways to small peptides and amino acids. No specific CYP450 enzymes are involved. |
| Excretion | Primarily catabolized to small peptides and amino acids; renal excretion of metabolites is minimal. No significant biliary or fecal elimination of intact drug. |
| Half-life | Approximately 46 hours (range 38–55 hours) in adults, supporting a 14-day intravenous dosing interval. |
| Protein binding | Approximately 99% bound to plasma proteins, primarily to human serum albumin. |
| Volume of Distribution | Approximately 0.09 L/kg (range 0.07–0.12 L/kg), indicating limited extravascular distribution, consistent with a monoclonal antibody confined primarily to the vascular space. |
| Bioavailability | Intravenous administration only; bioavailability is 100% by the IV route. Not absorbed after oral administration. |
| Onset of Action | Clinical effect (preservation of beta-cell function) observed within 3–6 months after initiation of treatment; immediate pharmacodynamic effects on T-cell markers occur within 24–48 hours post-dose. |
| Duration of Action | Duration of pharmacodynamic effect (suppression of activated T-cells) approximately 14 days, matching dosing interval. Clinical benefit lasts for at least 2 years based on trial follow-up. |
14-day course: Day 1: 12 mg/m2 IV; Day 2: 21 mg/m2 IV; Day 3-5: 36 mg/m2 IV; Day 6-8: 54 mg/m2 IV; Day 9-11: 70 mg/m2 IV; Day 12-14: 91 mg/m2 IV. Administer as IV infusion over 30 minutes.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m2). Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m2) or dialysis; use with caution. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment; use with caution. |
| Pediatric use | Approved for patients ≥8 years of age. Use same body surface area-based dosing as adults. For patients <8 years: not approved; no recommended dose. |
| Geriatric use | No specific dose adjustment. Clinical studies did not include sufficient numbers of patients ≥65 years to determine whether they respond differently. Use with caution due to potential comorbidities and decreased organ function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TZIELD (TZIELD).
| Breastfeeding | Unknown if teplizumab is excreted in human milk. Human IgG is present in breast milk, but minimal systemic absorption in the infant is expected. M/P ratio not available. Consider developmental and health benefits of breastfeeding along with maternal need for therapy. |
| Teratogenic Risk | No adequate human data. In animal studies, teplizumab (TZIELD) showed no evidence of fetal harm at doses up to 10 times the human clinical exposure. However, monoclonal antibodies are known to cross the placenta increasingly as pregnancy progresses, especially in the second and third trimesters. Risk cannot be excluded, and use should be avoided unless clearly needed. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to teplizumab or any component of the formulation","Active serious infection"]
| Precautions | ["Cytokine Release Syndrome (CRS): symptoms may include fever, headache, nausea, myalgia, chills, hypotension, and hypoxia; manage with supportive care.","Lymphopenia and neutropenia: monitor complete blood counts during and after treatment.","Infections: increased risk of serious infections; avoid use in patients with active infections.","Hypersensitivity reactions: including anaphylaxis; discontinue if severe.","Immunization: avoid live vaccines during treatment and until lymphocyte counts recover."] |
Loading safety data…
| Fetal Monitoring | Monitor for infusion reactions (hypotension, fever, rash) during administration. No specific fetal monitoring required; standard prenatal care. Monitor for infections as teplizumab may increase susceptibility. |
| Fertility Effects | No human data on fertility. Animal studies show no adverse effects on male or female fertility at doses up to 10 times the human exposure. |